// App-Quantinova.ai

3075 : Updates on phase1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma.

Researchers

Presenter

  • Yousef Zakharia

Principal Investigators

  • Joseph J. Drabick

  • Samir Khleif

  • Robert R. McWilliams

  • David Munn

  • Charles J. Link

  • Nicholas N. Vahanian

  • Eugene Kennedy

  • Montaser F. Shaheen

  • Olivier Rixe

  • Mohammed M. Milhem

Medical Centers

  • University of Iowa Hospitals and Clinics, Holden Comprehensive Cancer Center, Iowa City, IA

  • Penn State Milton S. Hershey Medical Center, Palmyra, PA

  • GRU Cancer Center, Georgia Regents University, Augusta, GA

  • Mayo Clinic, Rochester, MN

  • NewLink Genetics Corporation, Ames, IA

  • University of New Mexico Cancer Center, Albuquerque, NM

Locations

  • United States

Companies

  • NewLink Genetics Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

  • Indoximod

  • Nivolumab

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT02073123

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved